Annalisa Schiepatti1,2, Anupam Rej1, Stiliano Maimaris2, Simon S Cross3, Petra Porta2, Imran Aziz1, Tim Key4, John Goodwin4, Amelie Therrien5, Shakira Yoosuf5, Daniel A Leffler5, Jocelyn A Silvester6, Catherine Klersy7, Federico Biagi2, David S Sanders1. 1. Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK. 2. Gastroenterology Unit, IRCCS Pavia, ICS Maugeri, University of Pavia, Pavia, Italy. 3. Department of Histopathology, Royal Hallamshire Hospital, Sheffield, UK. 4. Histocompatibility and Immunogenetics Laboratory, NHS Blood and Transplant, Sheffield, UK. 5. Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 6. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 7. Unit of Clinical Epidemiology and Biometry, IRCCS Policlinico San Matteo, Pavia, Italy.
Abstract
BACKGROUND: Seronegative coeliac disease is poorly defined. AIMS: To study clinical phenotypes and long-term outcomes of seronegative coeliac disease in a multicentre cohort over 20 years. METHODS: Seronegative coeliac disease was diagnosed in HLA-DQ2/DQ8-positive patients with villous atrophy (VA), negative IgA endomysial (EmA), tissue transglutaminase (tTG) and deamidated-gliadin antibodies (DGP), clinical and histological response to a gluten-free diet (GFD), and no alternative causes for VA. In patients with IgA deficiency, coeliac disease was diagnosed through VA, positive IgG EmA/tTG/DGP and clinical/histological response to a GFD (coeliac disease+IgAd). Patients with seropositive coeliac disease served as controls. RESULTS: Of 227 patients previously diagnosed with seronegative coeliac disease, true seronegative coeliac disease was confirmed in 84, coeliac disease+IgAd in 48, and excluded in 55. Lack of follow-up duodenal biopsy precluded diagnosing seronegative coeliac disease in 40 patients. 2084 patients with seropositive coeliac disease served as controls. True seronegative coeliac disease had more severe symptoms at diagnosis and a higher risk of complications (HR 10.87, 95% CI 6.11-19.33, P < 0.001) and mortality (HR 2.18, 95% CI 1.12-4.26, P < 0.01) than seropositive coeliac disease. There were no differences between true seronegative coeliac disease and coeliac disease+IgAd. On multivariate analysis, age at diagnosis, lack of clinical response to a GFD, true seronegative coeliac disease, coeliac disease+IgAd, and classical presentation predicted complications. Age at diagnosis, complications and absence of clinical response to a GFD predicted mortality. CONCLUSIONS: Seronegative coeliac disease has a more aggressive disease phenotype than seropositive coeliac disease. These data argue against over-reliance on serology for the diagnosis of coeliac disease and support a strict clinical and histologic follow-up in seronegative coeliac disease.
BACKGROUND: Seronegative coeliac disease is poorly defined. AIMS: To study clinical phenotypes and long-term outcomes of seronegative coeliac disease in a multicentre cohort over 20 years. METHODS: Seronegative coeliac disease was diagnosed in HLA-DQ2/DQ8-positive patients with villous atrophy (VA), negative IgA endomysial (EmA), tissue transglutaminase (tTG) and deamidated-gliadin antibodies (DGP), clinical and histological response to a gluten-free diet (GFD), and no alternative causes for VA. In patients with IgA deficiency, coeliac disease was diagnosed through VA, positive IgG EmA/tTG/DGP and clinical/histological response to a GFD (coeliac disease+IgAd). Patients with seropositive coeliac disease served as controls. RESULTS: Of 227 patients previously diagnosed with seronegative coeliac disease, true seronegative coeliac disease was confirmed in 84, coeliac disease+IgAd in 48, and excluded in 55. Lack of follow-up duodenal biopsy precluded diagnosing seronegative coeliac disease in 40 patients. 2084 patients with seropositive coeliac disease served as controls. True seronegative coeliac disease had more severe symptoms at diagnosis and a higher risk of complications (HR 10.87, 95% CI 6.11-19.33, P < 0.001) and mortality (HR 2.18, 95% CI 1.12-4.26, P < 0.01) than seropositive coeliac disease. There were no differences between true seronegative coeliac disease and coeliac disease+IgAd. On multivariate analysis, age at diagnosis, lack of clinical response to a GFD, true seronegative coeliac disease, coeliac disease+IgAd, and classical presentation predicted complications. Age at diagnosis, complications and absence of clinical response to a GFD predicted mortality. CONCLUSIONS: Seronegative coeliac disease has a more aggressive disease phenotype than seropositive coeliac disease. These data argue against over-reliance on serology for the diagnosis of coeliac disease and support a strict clinical and histologic follow-up in seronegative coeliac disease.
Authors: R L J van Wanrooij; D M J Müller; E A Neefjes-Borst; J Meijer; L G Koudstaal; D A M Heideman; H J Bontkes; B M E von Blomberg; G Bouma; C J J Mulder Journal: J Clin Immunol Date: 2014-07-27 Impact factor: 8.317
Authors: Andrew D Hopper; Simon S Cross; David P Hurlstone; Mark E McAlindon; Alan J Lobo; Marios Hadjivassiliou; Marion E Sloan; Simon Dixon; David S Sanders Journal: BMJ Date: 2007-03-23
Authors: Pekka Collin; Katri Kaukinen; Harald Vogelsang; Ilma Korponay-Szabó; Rudolf Sommer; Elisabeth Schreier; Umberto Volta; Alessandro Granito; Lorenza Veronesi; Françoise Mascart; Annick Ocmant; Anneli Ivarsson; Carina Lagerqvist; Annemarie Bürgin-Wolff; Faruk Hadziselimovic; Raoul I Furlano; Marc A Sidler; Chris J J Mulder; Marije S Goerres; M Luisa Mearin; Maarten K Ninaber; Eivind Gudmand-Høyer; Elisabetta Fabiani; Carlo Catassi; Helena Tidlund; Lisbeth Alainentalo; Markku Mäki Journal: Eur J Gastroenterol Hepatol Date: 2005-01 Impact factor: 2.566
Authors: Marisa DeGaetani; Christina A Tennyson; Benjamin Lebwohl; Suzanne K Lewis; Hussein Abu Daya; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green Journal: Am J Gastroenterol Date: 2013-05 Impact factor: 10.864
Authors: Hugo A Penny; Anupam Rej; Elisabeth M R Baggus; Sarah H Coleman; Rosalie Ward; Graeme Wild; Gerd Bouma; Nick Trott; John A Snowden; Josh Wright; Simon S Cross; Marios Hadjivassiliou; David S Sanders Journal: Nutrients Date: 2022-07-05 Impact factor: 6.706
Authors: Annalisa Schiepatti; David S Sanders; Paola Baiardi; Giacomo Caio; Carolina Ciacci; Katri Kaukinen; Benjamin Lebwohl; Daniel Leffler; Georgia Malamut; Joseph A Murray; Kamran Rostami; Alberto Rubio-Tapia; Umberto Volta; Federico Biagi Journal: Gut Date: 2022-06-08 Impact factor: 31.793